Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL1577981 | 1.00 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Alanine SCHEMBL9653878 | 0.98 | SLC7A5 (0.39) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Alanine SCHEMBL7488681 | 0.88 | SLC7A5 (0.33) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL111113 | 0.84 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Valine SCHEMBL27662657 | 0.84 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Alanine SCHEMBL27615995 | 0.84 | SLC7A5 (0.53) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL21616532 | 0.84 | SLC7A5 (0.53) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL27894192 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL28176722 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H | |
| Alanine SCHEMBL27383707 | 0.81 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070178554-A1 | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins | NEURION PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| US-20240000896-A1 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | INVEX THERAPEUTICS LTD. (AU) | 2024-01-04 | — | — | US | disclosed |
| EP-4000630-B1 | INCRETIN FOR ELEVATED INTRACRANIAL PRESSURE TREATMENT | INVEX THERAPEUTICS LTD (AU) | 2023-12-13 | — | — | EP | disclosed |
| US-11738067-B2 | Elevated intracranial pressure treatment | INVEX THERAPEUTICS LTD. (AU) | 2023-08-29 | — | — | US | disclosed |
| WO-2023141679-A1 | DIMERS AND USES THEREFOR | THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (AU) | 2023-08-03 | — | — | WO | disclosed |
| EP-4000630-A1 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | Invex Therapeutics Ltd (AU) | 2022-05-25 | — | — | EP | disclosed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3188747-B1 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | INVEX THERAPEUTICS LTD (AU) | 2021-09-08 | — | — | EP | disclosed |
| US-20210030848-A1 | ELEVATED INTRACRANIAL PRESSURE TREATMENT | INVEX THERAPEUTICS LTD. (AU) | 2021-02-04 | — | — | US | disclosed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2007090198-A2 | FLUORESCENT ASSAYS USING ORTHOGONAL TRNA - AMINOACYL SYNTHETASE PAIRS | ENCODE BIO, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070178554-A1 | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins | NEURION PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007041833-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027225-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY AND DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SLC7A5 1653/4885SLC1A3 323/4885SLC1A2 518/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SLC7A5 1653/4885SLC1A3 323/4885SLC1A2 518/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | SLC7A5 532/4885SLC1A3 286/4885SLC1A2 130/4885 |
| US-20070178554-A1 | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins | AARS1, GARS1, TRMT1 | SLC7A5 171/4885SLC1A3 287/4885SLC1A2 334/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | SLC7A5 1653/4885SLC1A3 323/4885SLC1A2 518/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | SLC7A5 583/4885SLC1A3 282/4885SLC1A2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.